Former FDA head takes place on Pfizer board
Pfizer has appointed former US Food and Drug Administration commissioner Scott Gottlieb to its board.
UK gov to secure extra freight for medicine after no-deal Brexit
Industry has welcomed the British government’s announcement that it will take steps to secure additional freight capacity to deal with a shortage of pharmaceuticals in the event of a no-deal Brexit.
USPTO revives fight over CRISPR patents
The US Patent and Trademark Office has revived the dispute between the Broad Institute of MIT and Harvard and the University of California, Berkeley over which first invented the CRISPR gene-editing technology.
Novartis secures injunction barring generic MS drugs
A US court has issued an injunction barring the manufacture of generic versions of Swiss pharmaceutical company Novartis’ multiple sclerosis drug Gileyna.
AbbVie to acquire Allergan for $63bn
US drug maker AbbVie has agreed to buy Allergan, the Ireland-headquartered maker of Botox, for $63 billion, in the latest blockbuster deal for the pharmaceutical industry.
Cancer centre sues BMS and Ono over alleged patent exploitation
Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.
Teva infringed UCB patent, rules Fed Circuit
The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro, a patch to treat Parkinson’s disease.
Fed Circuit sides with Merck in antifungal treatment dispute
A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.
CMS promotes two to partnership in London
International law firm CMS has promoted two attorneys from its IP team in London to partner.
English High Court refuses to grant Pfizer Arrow declaration
Pfizer’s attempt to secure an Arrow declaration in relation to its proposed launch of a cancer drug in Europe was shot down yesterday, June 20, by the English High Court.
